Myron G. Hill

Array ( [id] => 18685188 [patent_doc_number] => 11780906 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-10 [patent_title] => Compositions and methods for the treatment of immunodeficiency [patent_app_type] => utility [patent_app_number] => 17/750470 [patent_app_country] => US [patent_app_date] => 2022-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 18 [patent_no_of_words] => 34283 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17750470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18732577 [patent_doc_number] => 11801297 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-31 [patent_title] => Vaccine against RSV [patent_app_type] => utility [patent_app_number] => 17/664290 [patent_app_country] => US [patent_app_date] => 2022-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 19 [patent_no_of_words] => 11802 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17664290 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19281995 [patent_doc_number] => 20240218469 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => COMPOSITIONS AND METHODS FOR DETECTING HUMAN ADENOVIRUS NUCLEIC ACID [patent_app_type] => utility [patent_app_number] => 18/558346 [patent_app_country] => US [patent_app_date] => 2022-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40464 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18558346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20192295 [patent_doc_number] => 20250269005 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-28 [patent_title] => METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT [patent_app_type] => utility [patent_app_number] => 18/290146 [patent_app_country] => US [patent_app_date] => 2022-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62110 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18290146 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20535776 [patent_doc_number] => 12552840 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-17 [patent_title] => Identification of inhibitor peptides to bind with n-terminal spike (s) and nonstructural protein (NSP) sequences of SARS-COV2 b.1.617.2 Delta or Omicron variants alone and combination with drug(s) for targeted antiviral therapy [patent_app_type] => utility [patent_app_number] => 17/736755 [patent_app_country] => US [patent_app_date] => 2022-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 1508 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17736755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19248738 [patent_doc_number] => 20240199725 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => HUMAN ANTIBODY TARGETING COVID-19 VIRUS [patent_app_type] => utility [patent_app_number] => 18/287139 [patent_app_country] => US [patent_app_date] => 2022-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14669 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18287139 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19232216 [patent_doc_number] => 20240189407 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => MODIFIED VIRUS-LIKE PARTICLES OF BACTERIOPHAGE AP205 [patent_app_type] => utility [patent_app_number] => 18/554935 [patent_app_country] => US [patent_app_date] => 2022-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27292 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18554935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17748263 [patent_doc_number] => 20220226466 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => PHARMACEUTICAL AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SARS-COV-2 [patent_app_type] => utility [patent_app_number] => 17/715741 [patent_app_country] => US [patent_app_date] => 2022-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14476 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17715741 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19447356 [patent_doc_number] => 20240307486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION [patent_app_type] => utility [patent_app_number] => 18/282730 [patent_app_country] => US [patent_app_date] => 2022-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 85148 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18282730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19432540 [patent_doc_number] => 20240301038 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => ANTIBODIES TO SARS-COV-2 [patent_app_type] => utility [patent_app_number] => 18/552107 [patent_app_country] => US [patent_app_date] => 2022-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31523 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18552107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19189108 [patent_doc_number] => 20240168021 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => LATERAL FLOW TEST METHODS [patent_app_type] => utility [patent_app_number] => 18/549625 [patent_app_country] => US [patent_app_date] => 2022-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8740 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18549625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17852182 [patent_doc_number] => 20220282224 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => PREVENTION OF VIRAL TRANSMISSION BY NAKED GENETIC MATERIAL [patent_app_type] => utility [patent_app_number] => 17/681206 [patent_app_country] => US [patent_app_date] => 2022-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9874 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17681206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18762945 [patent_doc_number] => 11813324 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-14 [patent_title] => Methods for immunizing pre-immune subjects against respiratory syncytial virus (RSV) [patent_app_type] => utility [patent_app_number] => 17/677399 [patent_app_country] => US [patent_app_date] => 2022-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 50 [patent_no_of_words] => 22594 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17677399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20824868 [patent_doc_number] => 12678410 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-07-14 [patent_title] => Respiratory syncytial virus (RSV) polyanhydride nanoparticle vaccine [patent_app_type] => utility [patent_app_number] => 17/674683 [patent_app_country] => US [patent_app_date] => 2022-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 12 [patent_no_of_words] => 2152 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17674683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20824868 [patent_doc_number] => 12678410 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-07-14 [patent_title] => Respiratory syncytial virus (RSV) polyanhydride nanoparticle vaccine [patent_app_type] => utility [patent_app_number] => 17/674683 [patent_app_country] => US [patent_app_date] => 2022-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 12 [patent_no_of_words] => 2152 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17674683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18207457 [patent_doc_number] => 20230053714 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS [patent_app_type] => utility [patent_app_number] => 17/668287 [patent_app_country] => US [patent_app_date] => 2022-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25994 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17668287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17719122 [patent_doc_number] => 20220211841 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => NUCLEIC ACID BASED COMBINATION VACCINES [patent_app_type] => utility [patent_app_number] => 17/665772 [patent_app_country] => US [patent_app_date] => 2022-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 110741 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17665772 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17719119 [patent_doc_number] => 20220211838 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => NUCLEIC ACID BASED COMBINATION VACCINES [patent_app_type] => utility [patent_app_number] => 17/665704 [patent_app_country] => US [patent_app_date] => 2022-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 110718 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17665704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17790563 [patent_doc_number] => 20220249654 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => NUCLEIC ACID BASED COMBINATION VACCINES [patent_app_type] => utility [patent_app_number] => 17/665808 [patent_app_country] => US [patent_app_date] => 2022-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 110765 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17665808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18077363 [patent_doc_number] => 20220402975 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => NEWCASTLE DISEASE VIRUS-BASED VECTORED VACCINE [patent_app_type] => utility [patent_app_number] => 17/592333 [patent_app_country] => US [patent_app_date] => 2022-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8528 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17592333 [rel_patent_id] =>[rel_patent_doc_number] =>)